Last reviewed · How we verify

Influenza Virus Vaccine Live, Intranasal

Tufts Medical Center · Phase 1 active Biologic

Influenza Virus Vaccine Live, Intranasal is a Biologic drug developed by Tufts Medical Center. It is currently in Phase 1 development. Also known as: FluMist.

At a glance

Generic nameInfluenza Virus Vaccine Live, Intranasal
Also known asFluMist
SponsorTufts Medical Center
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Influenza Virus Vaccine Live, Intranasal

What is Influenza Virus Vaccine Live, Intranasal?

Influenza Virus Vaccine Live, Intranasal is a Biologic drug developed by Tufts Medical Center.

Who makes Influenza Virus Vaccine Live, Intranasal?

Influenza Virus Vaccine Live, Intranasal is developed by Tufts Medical Center (see full Tufts Medical Center pipeline at /company/tufts-medical-center).

Is Influenza Virus Vaccine Live, Intranasal also known as anything else?

Influenza Virus Vaccine Live, Intranasal is also known as FluMist.

What development phase is Influenza Virus Vaccine Live, Intranasal in?

Influenza Virus Vaccine Live, Intranasal is in Phase 1.

Related